Reorganization of Executive Oversight Structure for the Development and Quality Control Divisions
First written in FY2018-Q3. 2 of 3 entries say "Advanced", first in FY2020-Q2. Latest entry: FY2021-Q3.
The whole theme swung hardest in 2026: 4 of 26 companies on the "Worse" side.
11 other companies' latest entry also says "Advanced".
- FY2021-Q3AdvancedAnnual report
「Representative Director and President / Head of Development Headquarters / Head of Corporate Planning Office → Representative Director and President / Head of Corporate Planning Office / Hatano Kazuhiro (秦野 和浩) / 1 December 2020」
Effective 1 December 2020, the responsibility structure for the Development Headquarters, international business, Europe and the United States and Asia, drug development and European operations was reorganized, including the Representative Director and President concurrently serving as Head of the Development Headquarters. - FY2020-Q2AdvancedAnnual report
「Senior Managing Director / Head of Development Headquarters → Senior Managing Director / Head of Development Headquarters and Head of International Business Development Headquarters / Miyazaki Masaya (宮崎 正哉) / 1 August 2019 Director / In charge of the Oncology Division, Development Headquarters → Director / In charge of the Oncology Contract Development Division / Sakamoto Isao (坂本 勲勇) / 1 August 2019 Director / Head of the Central Nervous System Division, Development Headquarters → Director / Head of the Central Nervous System Contract Development Division / Tajiri Kazuhiro (田尻 一裕) / 1 August 2019」
Effective 1 August 2019, the responsibilities and positions of the officers overseeing the International Business Development Headquarters, Oncology Division and Central Nervous System Division were changed, and the responsibility structure centered on the Development Headquarters was reorganized. - FY2018-Q3First statedAnnual report
「Representative Director President Representative Director President Head of Development Division Hatano Kazuhiro (秦野 和浩) 1 July 2017」
During the cumulative period under review, the positions and responsibilities of the officers in charge, including the heads of the Development Headquarters and Quality Management Headquarters, were changed. The executive structure for development and quality management was reorganized.